2011
DOI: 10.1093/cid/cir247
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Skin and Soft Tissue Infections Due to Community-Associated Methicillin-Resistant Staphylococcus aureus in Europe: The Role of Trimethoprim-sulfamethoxazole

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

2
6
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 8 publications
2
6
0
Order By: Relevance
“…The dominant resistance gene mediating trimethoprim resistance in MRSA and MSSA in Namibia was dfrG , similar to reports in other Africa countries . Moreover, dfrG was frequently detected in S. aureus from SSTIs in travelers returning from other African countries, suggesting that dfrG can be transmitted in populations with low antifolate resistance, such as found in North America and Europe …”
Section: Resultssupporting
confidence: 81%
“…The dominant resistance gene mediating trimethoprim resistance in MRSA and MSSA in Namibia was dfrG , similar to reports in other Africa countries . Moreover, dfrG was frequently detected in S. aureus from SSTIs in travelers returning from other African countries, suggesting that dfrG can be transmitted in populations with low antifolate resistance, such as found in North America and Europe …”
Section: Resultssupporting
confidence: 81%
“…In Europe, clindamycin is also recommended as the only treatment for SSTIs (De Angelis et al, 2011). The results of the current study showed that clindamycin resistance in CA-MRSA strains was high (92 %).…”
Section: Disscussionmentioning
confidence: 53%
“…Some guidelines advocate SXT as the compound of choice for empirical treatment of skin and soft-tissue infections caused by S. aureus [11,12] with the aim of reducing failure of empirical antibiotic treatment in the MRSA era. Based on the presented results and existing knowledge on SXT resistance in clinical isolates [6][7][8], however, this approach may require modification for African patients as well as travellers that have acquired S. aureus infections on the African continent [13].…”
Section: Discussionmentioning
confidence: 99%